| Breast cancer |
A phase Ib/II, multicenter, open-label study to evaluate the efficacy of AUY922 in combination with trastuzumab in patients with locally advanced or metasatatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-con |
Inclusion completed |
SE |
| Breast cancer |
A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination with Anastrozole, Compared to An-astrozole alone, in Post menopausal Women With Hormone Receptor positive, Endocrine T |
Open for inclusion |
FI |
| Breast cancer |
A prospective phase II study to evaluate alternations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression efter initial exposure to trastuzumab-taxane based treatment |
Inclusion completed |
SE |
| Breast cancer |
First in human study in HER2 positive primary breast cancer patient who are eligible for neoadjuvant chemotherapy |
Open for inclusion |
DK |
| Breast cancer |
Intra-hepatic chemotherapy in patient with non-resectable liver mestastases from breast cancer. Only patients without extrahepatic disease are included |
Open for inclusion |
DK |
| Breast cancer |
Intra-hepatic chemotherapy in patient with non-resectable liver metastases from breast cancer and limited extrahepatic disease |
Open for inclusion |
DK |
| Breast cancer |
Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer |
Open for inclusion |
SE |
| Breast cancer |
Randomized phase II study of afatinib alone or in combination with vinorelbine versus investigator’s choice of treatment in patients with HER2-positive breast cancer with pro-gressive brain metastases after trastuzumab or lapatinib based therapy |
Open for inclusion |
FI |
| Cholangiocarcinoma |
A phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic gemcitabine and capecitabine in combination with cetuximab in patient with non-resectable liver metastases from cholangiocarcinoma |
Open for inclusion |
DK |
| Colorectal cancer |
Assessmant of safety and immunogenicity of intradermal electroporation of tetwtCEA DNA in patients with colorectal cancer |
Inclusion completed |
SE |
| Colorectal cancer |
Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours |
Open for inclusion |
DK |
| Colorectal cancer |
Open-label , single-arm, phase II study of bevacizumab (Avastin) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer |
Open for inclusion |
FI |
| Colorectal cancer |
Randomized Double blind Placebo Controlled Gross-over Phase II study on the effects of Lactobacillus Rhamnosus GC supplementation in patients on 1st Line Chemotherapy treatment for Metastatic Coloretctal Cancer- the "lactAXE"- trial |
Inclusion completed |
FI |
| Colorectal cancer |
The international liver tumor group. Radiofrequency ablation versus stereotactic body radiation therapy for colorectal liver metastases: A randomized trial |
Open for inclusion |
SE |
| Esophageal cancer |
Follow up of Phase I study of radiotherapy and platinum-Fluouracil based chemotherapy with cetuximab in locally advanced esopgael cancer |
Open for inclusion |
DK |
| Gastric cancer |
Pazopanib in advanced gastrointestinal stromal tumors refractory to imatinib and sunutinib. A Non-comparative phase II multicenter study study by the Scandinavian Sarcoma Group |
Open for inclusion |
FI |
| Gastric cancer |
Phase I-II study of traztuzumab combined with docetaxel, oxaliplatin and capecitabine in advanced or metastatic gastic or cardia cancer |
Open for inclusion |
DK |
| Glioblastoma |
BIBF1120 in patient with glioblastoma and progression after standard therapy /temozolomide and radiotherapy (group 1) or after bevacizumab based secondline therapy (group 2) |
Inclusion completed |
DK |
| Glioblastoma |
DC-CAST-GBM |
Open for inclusion |
NO |
| Glioblastoma |
Electrochemotherapy as a Palliative Treatment for Brain Metastases |
Open for inclusion |
DK |
| Glioblastoma |
Phase I dose escalation of anti-PlGF combined with bevacizumab 10 mg/kg every 2 weeks in recurrent GBM |
Inclusion completed |
DK |
| Head and Neck cancer |
A multicentre, open label, randomised phase II study with or without induction chemotherapy, combined with radiotherapy and cetuximab (Erbitux®®) in locally advanced unresectable squamous cell carcinoma of the head & neck with HPV positive tumors |
Open for inclusion |
SE |
| Head and Neck cancer |
Boron neutron capture therapy (BNCT) for the treatment of inoperable head and neck cancer |
Open for inclusion |
FI |
| Hematological malignancies |
A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 inPatients with Advanced Hematological Malignancies |
Open for inclusion |
DK |
| Lung cancer |
A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment |
Open for inclusion |
NO |
| Lung cancer |
CAUY922A2206 NSCLC |
Open for inclusion |
NO |
| Lung cancer |
IDO Peptide Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients |
Open for inclusion |
DK |
| Lung cancer |
Open randomized phase-II trial of SBRT + chemotherapy vs chemotherapy in NSCLC patients with a maximum of 5 tumor lesions |
Open for inclusion |
SE |
| Lung cancer |
Phase I and II studies of intravenous sodium SElenite as a cytotoxic agent in advanced CARcinoma of the lung |
Open for inclusion |
SE |
| Lung cancer |
Phase II randomized study on Locally Advanced Non small cell lung cancer. Escalated dose on individual basis, treatment with radiochemotherapy |
Open for inclusion |
SE |
| Lymphoma |
A Two Stage Phase Ib Study to Investigate the Pharmocokinetics and Tolerability of Rituximab Subcutaneous Formulation in Pats With Follicular Lymphoma as Part of Maintenance Treatement |
Inclusion completed |
FI |
| Lymphoma |
Dose densified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk Diffuse Large B-Cell Lymphoma (NLG-LBC05) |
Open for inclusion |
FI |
| Lymphoma |
Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine,vindesine, temozolomi-de and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomi |
Inclusion completed |
FI |
| Lymphoma |
Open-label, uncontrolled phase II trial of intravenous PI3K inhibitor BAY-80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin´s lymphomas |
Open for inclusion |
FI |
| Lymphoma |
Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy. A randomized, open-label, multicentre phase II trial |
Open for inclusion |
SE |
| Lymphoma, Sarcoma |
Cross tumoral phase II clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET |
Open for inclusion |
NO |
| Melanoma |
A randomised Phase II study of MK-3475 versus Chemotherapy in Pateients with Advanced Melanoma |
Open for inclusion |
NO |
| Melanoma |
A single arm, open-label, phase II, multicentre study, to assess the safety of vismodegib(GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC) |
Open for inclusion |
SE |
| Melanoma |
CA184025 Malign melanoma (inop. III and IV) |
Inclusion completed |
NO |
| Melanoma |
CLGX818X2101 Locally advanced or mestastatic BRAF mutant melanoma |
Open for inclusion |
NO |
| Melanoma |
DC-004 Unresectable metastases (Stage III or IV M1a-c-Malign melanoma) |
Temporary closed for inclusion |
NO |
| Melanoma |
Safety and efficacy of intratumoural electrotransfer of Plasmid AMEP in patients suffering from advanced or metastatic melanoma: an open phase 1 trial |
Open for inclusion |
DK |
| Melanoma |
T-cell therapy for patients with malignant melanoma |
Open for inclusion |
DK |
| Melanoma |
Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma |
Open for inclusion |
DK |
| Multiple diagnosis |
C08-315-01 Transdermally accessible tumour |
Inclusion completed |
NO |
| Multiple diagnosis |
Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours |
Open for inclusion |
DK |
| Multiple diagnosis |
MOC31-PE Advanced mamma, lung, colorectal or prostate carcinoma |
Inclusion completed |
NO |
| Multiple diagnosis |
Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MKMK)in Patients with Advanced Cancer |
Open for inclusion |
NO |
| Myeloma |
A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma |
Inclusion completed |
DK |
| Myeloma |
Daratumumab (anti-CD38) in refractory multiple myeloma, first in humans |
Open for inclusion |
DK |
| Myeloma |
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma |
Open for inclusion |
DK |
| Oesophagus |
A phase II study with Oxaliplatin + 5-Fu + Cetuximab and radiotherapy for the treatment of non-resectable, locally advanced but not metastatic cancer of oesophagus or the cardia |
Open for inclusion |
SE |
| Ovarian cancer |
A phase II non comparative study with paclitaxel and carboplatin in combination with vorinostat in patients with advanced recurrent epithelia ovarian carcinoma |
Open for inclusion |
DK |
| Ovarian cancer |
DC-006 Recurrent ovarian epithelial cancer |
Open for inclusion |
NO |
| Pancreatic cancer |
A Phase I/II Trial and TG01 Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas |
Open for inclusion |
NO |
| Pancreatic cancer |
Bay86-9766 And Gemcitabine in PAncreatic Cancer (BAGPAC) |
Inclusion completed |
NO |
| Pancreatic cancer |
Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer |
Inclusion completed |
SE |
| Pancreatic cancer |
Safety, pharmacokinetics and efficacy of AXP107-11 in patients with standard gemcitabine (Gemzar®) treatment in patients with locally advanced or metastatic, unresectable, adenocarcinoma of the pancreas, stage III-IV. |
Open for inclusion |
SE |
| Prostate cancer |
A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer |
Open for inclusion |
FI |
| Prostate cancer |
A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer (ConCab) |
Open for inclusion |
SE |
| Prostate cancer |
DC-005 Prostate |
Open for inclusion |
NO |
| Prostate cancer |
Dendritic cell vaccination in combination with Docetaxel for patients with prostate cancer – a randomized phase II study |
Open for inclusion |
DK |
| Prostate cancer |
Open, single-arm, multicenter, phase II trial investigating the safety of biweekly cabazi-taxel in metastatic castration resistant prostate cancer patients previously treated with docetaxel-containing regimen |
Open for inclusion |
FI |
| Prostate cancer |
Safety and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer: open, non-randomised, uncontrolled, multicentre, multiple dose escalation study with randomised phase II expansion component |
Open for inclusion |
FI |
| Sarcoma |
A Scandinavian Sarcoma Group treatment protocol for adult patients with non-metastatic high-risk soft tissue sarcoma of the extremities and trunk wall |
Open for inclusion |
SE |
| Skin cancer |
Combined treatment with Autologous Dendritic cells and T cells in patients with advanced Melanoma |
Open for inclusion |
SE |
| Solide tumores |
A phase 1, open label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function |
Inclusion completed |
SE |
| Solide tumores |
A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients with Advanced or Metastatic Solid Tumor Malignancies |
Open for inclusion |
DK |
| Solide tumores |
A phase I, open-label study to evaluate the PK and safety of panobinostat in patients with advanced solid tumors and varying degrees of renal function |
Open for inclusion |
SE |
| Solide tumores |
A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Patients With Metastatic and/or Locally Advanced Malignant HER3-Positive Solid Tumors |
Open for inclusion |
DK |
| Solide tumores |
An open non-randomized study to investigate the local tumour control rate in patients with centrally located lung lesions who receive treatment with Stereotactic body radiotherapy |
Open for inclusion |
SE |
| Solide tumores |
CMEK162X2102 All solid tumors with BRAF or RAF mutation |
Inclusion completed |
NO |
| Solide tumores |
First study of intravenous catumaxumab (Removab) in patients with EpCam expressing epithelial solid tumors |
Inclusion completed |
DK |
| Solide tumores |
Second generation Braf inhibitor (after lead compound vemurafenib) in Braf mutated solid tumors, and extension phase in melanomas and colorectal cancer |
Inclusion completed |
DK |
| Solide tumores |
TWEAK-antibody in patients with Fn14 expressing solid tumors, first in humans study |
Inclusion completed |
DK |
| Urothelial |
A phase II open label, single arm study evaluating treatment with pazopanib post sunitinib treatment in patients with mRCC. |
Open for inclusion |
SE |
| Urothelial |
An exploratory Phase I Study with Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract |
Open for inclusion |
SE |
